Transparency in Science Collaborations

The Bayer Science Collaboration Explorer started with contract-based research collaborations in Germany in September 2021 and was extended to the United States in December 2022. Since February 2024, data is also being disclosed for Switzerland and since November 2024 also for Brazil. The disclosed partner types are universities, public research institutions, and individuals. The scope of the BSCE will be extended stepwise.

Please find here a detailed definition of the in-scope partner types:

• Universities: Institutions of higher learning providing facilities for teaching/research and authorized to grant academic degrees (including Medical Schools & University Hospitals) 
• Public Research Institutions: Non-university and non-enterprise research-focused organizations with a considerable part of public funding
• Individuals: Science experts except of Health Care Professionals – in accordance with data privacy laws
   

Commercial businesses and Healthcare Professionals (HCPs) are currently excluded; however, collaborations with HCPs are covered by Bayer’s “Transfer of Value” initiative and therefore not duplicated here.

Balancing the transparency requirements of the public with confidentiality needs of Bayer and our partners, the following details are disclosed for each collaboration listed above: 

• ID: External reference number assigned to every disclosed collaboration
• Division: Name of partnering Bayer division (Pharmaceuticals, Crop Science, Consumer Health or Enabling Functions) 
• Subject of Collaboration: Meta category that best represents the scientific area of the collaboration
• Collaboration Type: Meta category that best represents the type of collaboration (Advisory Board Agreement, Consultancy Agreement, R&D Agreement, Speaker Agreement, Sponsorship Agreement, Other Agreement)
• Contract Partner(s): Name of partnering legal entity or individual (in case a partner does not consent to the disclosure, the partner's name gets anonymized (“undisclosed”) – in accordance with the law)
• Country of Partner(s): Partner’s country of incorporation / residence
• Country of Bayer Legal Entity: Bayer legal entity’s country of incorporation
• Funding Committed: Financial range of total funding committed by Bayer over the entire contract duration – might get adjusted retroactively based in actuals or proactively in case of contract amendments (ranges: 0 Euro; 1 - 10.000 Euro; 10.001 - 100.000 Euro; 100.001 - 500.000 Euro; 500.001 - 1.000.000 Euro; 1.000.001 - 5.000.000 Euro; 5.000.001 - 10.000.000 Euro; 10.000.001 - 25.000.000 Euro; 25.000.001 Euro +); for all financial ranges, additional non-monetary transfer of value may apply which are not listed here. These can include for example materials or know-how transfer.
• Effective Date: Date as of which the collaboration becomes effective
• Status: Indication whether collaboration is ongoing (active) or completed (inactive) 

Please find a more detailed Q&A document